Articles with public access mandates - Anthony El-KhoueiryLearn more
Available somewhere: 21
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ...
The Lancet 389 (10088), 2492-2502, 2017
Mandates: US National Institutes of Health, National Institute for Health Research, UK
Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
GK Abou-Alfa, T Meyer, AL Cheng, AB El-Khoueiry, L Rimassa, BY Ryoo, ...
New England Journal of Medicine 379 (1), 54-63, 2018
Mandates: US National Institutes of Health
Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a …
AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ...
Jama 317 (23), 2392-2401, 2017
Mandates: US National Institutes of Health
Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ...
Journal of Clinical Oncology 36 (3), 276-282, 2018
Mandates: US National Institutes of Health
Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline
RT Shroff, EB Kennedy, M Bachini, T Bekaii-Saab, C Crane, J Edeline, ...
Journal of Clinical Oncology 37 (12), 1015-1027, 2019
Mandates: US National Institutes of Health, Cancer Research UK, National Institute for …
SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and …
E Ben-Josef, KA Guthrie, AB El-Khoueiry, CL Corless, MM Zalupski, ...
Journal of Clinical Oncology 33 (24), 2617-2622, 2015
Mandates: US National Institutes of Health
AKT Inhibition in Solid Tumors With AKT1 Mutations
DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...
Journal of Clinical Oncology 35 (20), 2251-2259, 2017
Mandates: US National Institutes of Health, Cancer Research UK
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
AB El-Khoueiry, CJ Rankin, E Ben-Josef, HJ Lenz, PJ Gold, RD Hamilton, ...
Investigational new drugs 30, 1646-1651, 2012
Mandates: US National Institutes of Health
Impact of sex on the survival of patients with hepatocellular carcinoma: a surveillance, epidemiology, and end results analysis
D Yang, DL Hanna, J Usher, J LoCoco, P Chaudhari, HJ Lenz, ...
Cancer 120 (23), 3707-3716, 2014
Mandates: US National Institutes of Health
Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer …
G Lurje, F Nagashima, W Zhang, D Yang, HM Chang, MA Gordon, ...
Clinical Cancer Research 14 (23), 7884-7895, 2008
Mandates: US National Institutes of Health
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
AB El-Khoueiry, C Rankin, AB Siegel, S Iqbal, IY Gong, KC Micetich, ...
British journal of cancer 110 (4), 882-887, 2014
Mandates: US National Institutes of Health
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer
A Gerger, A El-Khoueiry, W Zhang, D Yang, H Singh, P Bohanes, Y Ning, ...
Clinical Cancer Research 17 (17), 5783-5792, 2011
Mandates: US National Institutes of Health
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models
MJ LaBonte, PM Wilson, W Fazzone, J Russell, SG Louie, A El-Khoueiry, ...
Cancer research 71 (10), 3635-3648, 2011
Mandates: US National Institutes of Health
Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer
OA Press, W Zhang, MA Gordon, D Yang, G Lurje, S Iqbal, A El-Khoueiry, ...
Cancer research 68 (8), 3037-3042, 2008
Mandates: US National Institutes of Health
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study
NS Azad, A El-Khoueiry, J Yin, AL Oberg, P Flynn, D Adkins, A Sharma, ...
Oncotarget 8 (21), 35326, 2017
Mandates: US National Institutes of Health
A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy
PM Wilson, A El-Khoueiry, S Iqbal, W Fazzone, MJ LaBonte, S Groshen, ...
Cancer chemotherapy and pharmacology 65, 979-988, 2010
Mandates: US National Institutes of Health
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine
EM Newman, RJ Morgan, S Kummar, JH Beumer, MS Blanchard, C Ruel, ...
Cancer chemotherapy and pharmacology 75, 537-546, 2015
Mandates: US National Institutes of Health
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
AB El-Khoueiry, RK Ramanathan, DY Yang, W Zhang, S Shibata, ...
Investigational new drugs 30, 1175-1183, 2012
Mandates: US National Institutes of Health
Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma
G Lurje, H Husain, DG Power, D Yang, S Groshen, A Pohl, W Zhang, ...
Annals of oncology 21 (1), 78-86, 2010
Mandates: US National Institutes of Health
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with …
A Pohl, A El-Khoueiry, D Yang, W Zhang, G Lurje, Y Ning, T Winder, ...
The pharmacogenomics journal 13 (2), 173-180, 2013
Mandates: US National Institutes of Health, Cancer Research UK
Publication and funding information is determined automatically by a computer program